METTL1-mediated m7G modification of NEK1 mRNA promotes the proliferation of oral squamous cell carcinoma
- PMID: 40562282
- DOI: 10.1016/j.bbadis.2025.167961
METTL1-mediated m7G modification of NEK1 mRNA promotes the proliferation of oral squamous cell carcinoma
Abstract
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor found in the head and neck region, representing a significant public health concern. The 7-methylguanylate (m7G) RNA modification is a newly recognized regulatory mechanism influencing gene expression, and methyltransferase-like 1 (METTL1) has been linked to tumor progression in various cancers; however, its specific role in OSCC remains largely unexplored. This study reveals that METTL1 expression is notably increased in OSCC and correlates with a poor prognosis for patients. Functional assays indicate that reducing METTL1 levels inhibits OSCC cell proliferation both in laboratory settings and in animal models, resulting in a G1 phase cell cycle arrest. To delve deeper into the mechanisms at play, we utilized m7G Methylated RNA Immunoprecipitation Sequencing (m7G MeRIP-seq) alongside RNA sequencing (RNA-seq) to pinpoint the downstream targets of METTL1 in OSCC cells. Our results confirm that METTL1-catalyzed m7G modification on the 5' untranslated region (5'UTR) of NEK1 mRNA enhances its stability and positively regulates NEK1 expression. Additionally, silencing NEK1 also inhibits OSCC cell proliferation, diminishes clonogenic formation, and induces G1 phase cell cycle arrest. These findings indicate that METTL1-mediated m7G modification is vital for OSCC proliferation, with NEK1 identified as a significant downstream target. In conclusion, METTL1 stands out as a potential prognostic marker and therapeutic target in OSCC, highlighting the need for further exploration of its molecular mechanisms and clinical implications.
Keywords: METTL1; NEK1; Oncogenic signaling; Oral squamous cell carcinoma; m7G RNA modification; mRNA stability.
Copyright © 2025 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Bioinformatics identification and validation of m6A/m1A/m5C/m7G/ac4 C-modified genes in oral squamous cell carcinoma.BMC Cancer. 2025 Jul 1;25(1):1055. doi: 10.1186/s12885-025-14216-7. BMC Cancer. 2025. PMID: 40597017 Free PMC article.
-
Metabolic reprogramming driven by METTL1-mediated tRNA m7G modification promotes acquired anlotinib resistance in oral squamous cell carcinoma.Transl Res. 2024 Jun;268:28-39. doi: 10.1016/j.trsl.2024.01.009. Epub 2024 Jan 26. Transl Res. 2024. PMID: 38280546
-
VIRMA utilizes m6A-IGF2BP2 to mediate NDRG1, thereby increasing sensitivity to iron-chelating agents and subsequently inhibiting the proliferation and metastasis of oral squamous cell carcinoma.Cell Signal. 2025 Nov;135:111961. doi: 10.1016/j.cellsig.2025.111961. Epub 2025 Jun 26. Cell Signal. 2025. PMID: 40581266
-
Exploring the role of m7G modification in Cancer: Mechanisms, regulatory proteins, and biomarker potential.Cell Signal. 2024 Sep;121:111288. doi: 10.1016/j.cellsig.2024.111288. Epub 2024 Jul 5. Cell Signal. 2024. PMID: 38971569 Review.
-
Dysregulated PI3K/AKT signaling in oral squamous cell carcinoma: The tumor microenvironment and epigenetic modifiers as key drivers.Oncol Res. 2025 Jul 18;33(8):1835-1860. doi: 10.32604/or.2025.064010. eCollection 2025. Oncol Res. 2025. PMID: 40746882 Free PMC article. Review.
Cited by
-
METTL1 in human cancers: recognition of their functions, mechanisms and therapeutic value.Oncol Rev. 2025 Jul 30;19:1637372. doi: 10.3389/or.2025.1637372. eCollection 2025. Oncol Rev. 2025. PMID: 40809384 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical